Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - metformin hydrochloride, quantity: 850 mg; sitagliptin phosphate monohydrate, quantity: 64.25 mg - tablet - excipient ingredients: microcrystalline cellulose; sodium stearylfumarate; povidone; sodium lauryl sulfate; titanium dioxide; purified talc; iron oxide red; polyvinyl alcohol; iron oxide black; macrogol 3350 - janumet (sitagliptin phosphate monohydrate and metformin hydrochloride) is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both sitagliptin and metformin is appropriate.,[see sections 5.1 pharmacodynamic properties, clinical trials and 4.2 dose and method of administration].

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - sitagliptin phosphate monohydrate, quantity: 64.25 mg; metformin hydrochloride, quantity: 500 mg - tablet - excipient ingredients: povidone; microcrystalline cellulose; sodium stearylfumarate; sodium lauryl sulfate; titanium dioxide; purified talc; iron oxide red; polyvinyl alcohol; iron oxide black; macrogol 3350 - janumet (sitagliptin phosphate monohydrate and metformin hydrochloride) is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both sitagliptin and metformin is appropriate.,[see sections 5.1 pharmacodynamic properties, clinical trials and 4.2 dose and method of administration].

Ireland - English - HPRA (Health Products Regulatory Authority)

fresenius kabi limited - glucose anhydrous - solution for infusion - 10 %w/v - carbohydrates

Ireland - English - HPRA (Health Products Regulatory Authority)

fresenius kabi limited - glucose anhydrous - solution for infusion - 10 %w/v - carbohydrates

Ireland - English - HPRA (Health Products Regulatory Authority)

fresenius kabi limited - glucose anhydrous - solution for infusion - 10 %w/v - carbohydrates

Ireland - English - HPRA (Health Products Regulatory Authority)

fresenius kabi limited - glucose anhydrous - solution for infusion - 10 %w/v - carbohydrates

New Zealand - English - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - glucose monohydrate 10% - solution for infusion - 10 % - active: glucose monohydrate 10% - hypertonic infusion solutions are indicated: - as a source of energy incorporated with parenteral nutrition with minimal dilution effect - for use with an appropriate protein (nitrogen) source in the prevention of nitrogen loss or in the treatment of negative nitrogen balance in patients where: a) the alimentary tract cannot or should not be used b) gastrointestinal absorption of protein is impaired c) metabolic requirements for protein are substantially increased, as with extensive burns.

New Zealand - English - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - glucose monohydrate 25% - solution for infusion - 25 % - active: glucose monohydrate 25% - hypertonic infusion solutions are indicated: - as a source of energy incorporated with parenteral nutrition with minimal dilution effect - for use with an appropriate protein (nitrogen) source in the prevention of nitrogen loss or in the treatment of negative nitrogen balance in patients where: a) the alimentary tract cannot or should not be used b) gastrointestinal absorption of protein is impaired c) metabolic requirements for protein are substantially increased, as with extensive burns.

New Zealand - English - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - glucose monohydrate 50% - solution for infusion - 50 % - active: glucose monohydrate 50% - hypertonic infusion solutions are indicated: - as a source of energy incorporated with parenteral nutrition with minimal dilution effect - for use with an appropriate protein (nitrogen) source in the prevention of nitrogen loss or in the treatment of negative nitrogen balance in patients where: a) the alimentary tract cannot or should not be used b) gastrointestinal absorption of protein is impaired c) metabolic requirements for protein are substantially increased, as with extensive burns.

New Zealand - English - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - glucose monohydrate 70% - solution for infusion - 70 % - active: glucose monohydrate 70% - hypertonic infusion solutions are indicated: - as a source of energy incorporated with parenteral nutrition with minimal dilution effect - for use with an appropriate protein (nitrogen) source in the prevention of nitrogen loss or in the treatment of negative nitrogen balance in patients where: a) the alimentary tract cannot or should not be used b) gastrointestinal absorption of protein is impaired c) metabolic requirements for protein are substantially increased, as with extensive burns.